Coya Therapeutics Statistics
Share Statistics
Coya Therapeutics has 16.71M shares outstanding. The number of shares has increased by 5.7% in one year.
| Shares Outstanding | 16.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.53M |
| Failed to Deliver (FTD) Shares | 706 |
| FTD / Avg. Volume | 0.79% |
Short Selling Information
The latest short interest is 196.52K, so 1.18% of the outstanding shares have been sold short.
| Short Interest | 196.52K |
| Short % of Shares Out | 1.18% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 1.5 |
Valuation Ratios
The PE ratio is -9.43 and the forward PE ratio is -5.8.
| PE Ratio | -9.43 |
| Forward PE | -5.8 |
| PS Ratio | 12.55 |
| Forward PS | 12.1 |
| PB Ratio | 2.11 |
| P/FCF Ratio | -6.73 |
| PEG Ratio | n/a |
Enterprise Valuation
Coya Therapeutics Inc. has an Enterprise Value (EV) of 42.69M.
| EV / Earnings | -5.34 |
| EV / Sales | 7.11 |
| EV / EBITDA | -5.4 |
| EV / EBIT | -5.4 |
| EV / FCF | -3.82 |
Financial Position
The company has a current ratio of 8.15, with a Debt / Equity ratio of 0.
| Current Ratio | 8.15 |
| Quick Ratio | 8.15 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -24.39%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -24.39% |
| Revenue Per Employee | 750.28K |
| Profits Per Employee | -998.48K |
| Employee Count | 8 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 723.85K |
| Effective Tax Rate | -0.1 |
Stock Price Statistics
The stock price has increased by -20.44% in the last 52 weeks. The beta is 0.79, so Coya Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.79 |
| 52-Week Price Change | -20.44% |
| 50-Day Moving Average | 7.11 |
| 200-Day Moving Average | 7.39 |
| Relative Strength Index (RSI) | 39.68 |
| Average Volume (20 Days) | 88.92K |
Income Statement
In the last 12 months, Coya Therapeutics had revenue of $6.00M and earned -$7.99M in profits. Earnings per share was $-0.79.
| Revenue | 6.00M |
| Gross Profit | 5.97M |
| Operating Income | -7.90M |
| Net Income | -7.99M |
| EBITDA | -7.90M |
| EBIT | -7.90M |
| Earnings Per Share (EPS) | -0.79 |
Balance Sheet
The company has $32.63M in cash and $0 in debt, giving a net cash position of $32.63M.
| Cash & Cash Equivalents | 32.63M |
| Total Debt | 0 |
| Net Cash | 32.63M |
| Retained Earnings | -25.86M |
| Total Assets | 35.55M |
| Working Capital | 33.19M |
Cash Flow
In the last 12 months, operating cash flow was -$11.19M and capital expenditures $0, giving a free cash flow of -$11.19M.
| Operating Cash Flow | -11.19M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.19M |
| FCF Per Share | -1.1 |
Margins
Gross margin is 99.54%, with operating and profit margins of -131.67% and -133.08%.
| Gross Margin | 99.54% |
| Operating Margin | -131.67% |
| Pretax Margin | -121.02% |
| Profit Margin | -133.08% |
| EBITDA Margin | -131.67% |
| EBIT Margin | -131.67% |
| FCF Margin | -186.41% |
Dividends & Yields
COYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.72% |
| FCF Yield | -11.63% |
Analyst Forecast
The average price target for COYA is $16.5, which is 186.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.5 |
| Price Target Difference | 186.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 16.42 |
| Piotroski F-Score | 3 |